1. Table of studies ineligible for meta‐analysis.

Study ID	Reasons for ineligibility	Comparisons	Conclusions
Isik 2016	Primary endpoint: acute effects of sugammadex and neostigmine on renal function	Sugammadex 4 mg /kg at reappearance of PTC 1 to 2 or T2 vs neostigmine 40 µg/kg + atropine 10 µg/kg at reappearance of T2	We believe that the use of more specific and sensitive new‐generation markers such as Cystatin C to evaluate kidney function will provide better understanding and interpretation of our results. Sugammadex has more tolerable effects on kidney function than does neostigmine. However, when compared with preoperative values, negative alteration of postoperative values can be seen. Neostigmine and sugammadex do not cause renal failure but may affect kidney function
Kvolik 2012a	TOFR recovery data available only as mean, no data on standard deviation, study author has not replied	Sugammadex 2 mg/kg vs neostigmine 50 µg/kg	Recovery of cough reflexes was faster and respiration more efficient in patients receiving sugammadex. Safe extubation was determined by age, TOFR recovery, and effects of other anaesthetics
Kvolik 2013	TOFR recovery data available only as mean, no data on standard deviation, study author has not replied	Sugammadex 2 mg/kg vs neostigmine 50 µg/kg + atropine 25 µg/kg	An increase in BIS Index registered after reversal of rocuronium effects was faster during the recovery period in patients who were given sugammadex as compared with neostigmine. Although rapid increase in BIS Indices was registered in sugammadex group, more sensitive measurements are needed to confirm clinical value of this observation
Martini 2014	Primary endpoint: influence of depth of the NMB on SRS (surgical rating score)	Neostigmine 1 to 2 mg + atropine 0.5 to 1 mg (for reversal of moderate NMB) vs sugammadex 4 mg/kg (for reversal of deep NMB)	Application of 5‐point SRS showed that deep NMB results in improved quality of surgical conditions compared with moderate block in retroperitoneal laparoscopy, without compromise to patients’ perioperative and postoperative cardiorespiratory conditions
Rahe‐Meyer 2014	Comparison: sugammadex 4 mg/kg vs usual care (neostigmine with glycopyrrolate or atropine, or placebo/spontaneous recovery). Study author has not replied with separate data on neostigmine with glycopyrrolate or atropine or placebo/spontaneous recovery.	Sugammadex 4 mg/kg vs usual care (neostigmine with glycopyrrolate or atropine, or placebo/spontaneous recovery)	Sugammadex produced limited, transient (< 1 hour) increases in activated partial thromboplastin time and prothrombin time but was not associated with increased risk of bleeding vs usual care
Raziel 2013	No useable data available for quantitative meta‐analysis on recovery time or risk of adverse events	Sugammadex 2 mg/kg vs neostigmine 50 µg/kg + atropine 10 µg/kg	Sugammadex facilitates reversal of neuromuscular blockade after bariatric surgery, depending on the depth of neuromuscular blockade induced
Riga 2014	Primary outcome: cognitive function assessed by change in Mini‐Mental State Evaluation test (MMSE), Clock Drawing Test, and Isaacs Set Test, performed preoperatively, 1 hour postoperatively, and at discharge (1 to 15 days postoperatively)	Sugammadex vs neostigmine/atropine	No significant difference was observed regarding cognitive function after neostigmine/atropine combination or sugammadex was received for reversal of rocuronium‐induced neuromuscular blockade for elective surgery
Sherman 2014	Primary outcome: postoperative complications, data not available in useful format	Sugammadex 2 mg/kg vs neostigmine 2.5 mg/kg	Use of sugammadex (compared with neostigmine) as reversal agent following laparoscopic sleeve gastrectomy; surgery was associated with higher postoperative oxygen saturation despite lower TOF count before administration of reversal agent. Lack of differences in other measured variables may stem from the small size of patient groups studied
Sustic 2012	Outcome: gastric emptying evaluated by paracetamol absorption test	Sugammadex 2 mg/kg vs neostigmine 40 µg/kg + atropine group 15 µg/kg	Although study results show a tendency toward faster gastric emptying in sugammadex group, this difference is not significant in most, possibly owing to small sample size in this study
Tas 2015	Aim: to evaluate effects of sugammadex on postoperative nausea‐vomiting, pain, coagulation parameters, and quantity of postoperative bleeding. Data not available in useful format	Neostigmine 0.05 mg/kg + atropine 0.02 mg/kg vs sugammadex 2 mg/kg	Sugammadex was associated with greater postoperative bleeding than neostigmine in septoplasty patients. For surgical procedures with high risk of bleeding, the safety of sugammadex needs to be verified

Acronyms:

BIS ‐ Bispectral Index

MMSE ‐ Mini‐Mental State Examination

NMB ‐ neuromuscular blockade

T2 ‐ second twitch in train‐of‐four stimulation

TOFR ‐ train‐of‐four ratio

PTC ‐ post‐tetanic count

SRS ‐ surgical rating score